0000950170-24-023918.txt : 20240301 0000950170-24-023918.hdr.sgml : 20240301 20240301162956 ACCESSION NUMBER: 0000950170-24-023918 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240226 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001327273 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39273 FILM NUMBER: 24710381 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-373-4600 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: 480 Biomedical, Inc. DATE OF NAME CHANGE: 20120927 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Vascular, Inc. DATE OF NAME CHANGE: 20110826 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Medical, Inc. DATE OF NAME CHANGE: 20090414 8-K 1 lyra-20240226.htm 8-K 8-K
false000132727300013272732024-02-262024-02-26

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2024

 

 

Lyra Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39273

84-1700838

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

480 Arsenal Way

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 393-4600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

LYRA

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 26, 2024, the Board of Directors of Lyra Therapeutics, Inc. approved an increase in the annual salary of Harlan Waksal, M.D., Lyra’s Executive Chair, from $200,000 to $400,000, retroactive to January 1, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Lyra Therapeutics, Inc.

 

 

 

 

Date:

March 1, 2024

By:

/s/ Jason Cavalier

 

 

 

Jason Cavalier, Chief Financial Officer

 

 EX-101.SCH 2 lyra-20240226.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 3 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 26, 2024
Entity Registrant Name Lyra Therapeutics, Inc.
Entity Central Index Key 0001327273
Entity Emerging Growth Company true
Entity File Number 001-39273
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-1700838
Entity Address, Address Line One 480 Arsenal Way
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 393-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol LYRA
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports lyra-20240226.htm lyra-20240226.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lyra-20240226.htm": { "nsprefix": "lyra", "nsuri": "http://lyratherapeutics.com/20240226", "dts": { "inline": { "local": [ "lyra-20240226.htm" ] }, "schema": { "local": [ "lyra-20240226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_46c50d15-4ffc-4fd0-ac10-acf5427b4194", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240226.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_46c50d15-4ffc-4fd0-ac10-acf5427b4194", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lyra-20240226.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://lyratherapeutics.com/20240226/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 12 0000950170-24-023918-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-023918-xbrl.zip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lyra-20240226_htm.xml IDEA: XBRL DOCUMENT 0001327273 2024-02-26 2024-02-26 false 0001327273 8-K 2024-02-26 Lyra Therapeutics, Inc. DE 001-39273 84-1700838 480 Arsenal Way Watertown MA 02472 617 393-4600 false false false false Common Stock, $0.001 par value per share LYRA NASDAQ true false